abstract: The aim of the study was to investigate the effects of urinary follicle-stimulating hormone (FSH) compounds on the electrical activity of myometrium using signal-processing techniques. Thirty animals were involved in the experiment. After two successive normal estrous cycles, 15 of these animals were put into three equal subgroups. Group 1 was the control; animals were given solvent. Groups 2 and 3 were treated with Urofollitropin and Menotropin, respectively. The other 15 animals were ovariectomized and subjected to the same protocol. Their uterine myoelectrical signals were recorded over a period of at least 3 min at a sampling frequency of 500 Hz, and analyzed through software assisted signal processing. The results show the power and some characteristic spectral components of myoelectrical signal were differentially reduced with the administration of highly purified urinary FSH and human menopausal FSH but significant differences were not detected between their histology. In conclusion, uterine myoelectrical signals change with administration of urinary FSH preparations. Human menopausal FSH and more precisely highly purified FSH suppress the spectral components and modify the power of the myoelectrical signals which provides uterine quiescence.
Introduction
Adequate myometrial contractions may help in gamete or sperm transportation (Bulletti et al., 1997) . However, for a successful embryo implantation uterine quiescence is considered as very important (Bulletti et al., 1997) . Despite the progress toward understanding of the mechanism underlying uterine smooth-muscle contractions, the potential to identify dyskinetic changes in uterine myoelectrical activity in women undergoing ovarian stimulation, is still limited (Celik et al., 2008a, b) .
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) together control steroid secretion and gamete development in females. Presence of LH and FSH receptors in non-gonadal tissues, including uterus of pigs, rats and human, has been documented in various studies (Ziecik et al., 1992; Kornyei et al., 1996; Celik et al., 2008a) . The LH has been discussed as regulating glandular and luminal epithelial cell function in endometrium via cAMP modulation or by increasing the local synthesis of steroid hormones (Ziecik et al., 1992) . LH receptors are present in longitudinal, circular and vascular smooth muscles in myometrium. The FSH receptors are found in the form of mRNA transcripts and proteins in myometrium (Kornyei et al., 1996) . Also, FSH is known to directly act on endometrium, resulting in decidualization of endometrial stromal cells (Tang and Gurpide, 1993) . FSH receptors have also been found in the cervix (Mizrachi and Shemesh 1999a, b) , and they are speculated to mediate the uterine relaxation (Bulletti et al., 1997) . Both recombinant and urinary FSH are extensively used in assisted reproduction to trigger the ovaries for ovulation induction. These synthetic FSH preparations and the pituitary FSH have similar bioactivities but the rFSH preparations have substantial variations in size and structure of the carbohydrate chains and various levels of sialylation and sulfation (Green and Baenziger, 1998; Gervais et al., 2003; Wolfenson et al., 2005) that induces specific effects on the uterus. In our previous study, we have demonstrated the effect of rFSH preparations on the uterine myoelectrical activity (Celik et al., 2008a) . So far the influence of urinary FSH compounds on uterine electrical signal and, accordingly, on uterine contractions has not been adequately investigated. We, therefore, designed our experiment to investigate the effects of highly purified urinary FSH (HP-uFSH: urofollitropin) and human menopausal gonadotrophin (hMG: menotropin) on the myoelectrical properties of rat myometrium by using a computerized recording system as had been previously used by our group (Celik et al., 2008a, b) .
Materials and Methods

Animals
This study was carried out in the Experimental Research Laboratory of the Inonu University Faculty of Medicine, complying with the approval of the ethic committee and the guidelines for care and use of experimental animals. Thirty mature, healthy, 4-month-old female rats of Wistar strain, weighing between 200 and 250 g and having a 4 -5 day regular estrous cycle, were used in the study. The animals were kept under standard conditions: 12-h light and 12-h dark periods, 208C constant temperature, and a humidity range between 40 and 60%. The rats had free access to standard dry pellets ad libitum and tap water until the end of the study. Daily vaginal smears were taken to determine the estrous cycle of each animal as per established protocol (Hascalik et al., 2005) . The rats were monitored at least for two successive 5-day estrous cycles, and then they were randomized and studied.
Treatment
The subjects (n ¼ 30) involved in the experiment were equally divided into two prime groups.
Ovulation induction
Rats undergoing ovulation induction (n ¼ 15) were equally divided into three groups. Group 1 (control) animals were given solvent. Groups 2 and 3 were treated with Urofollitropin (Fostimon, IBSA Institut Biochemique, SA Lugano 3, Suisse) and Menotropin (Merional, IBSA Institut Biochemique, SA Lugano 3, Suisse), respectively. The treatment period was defined as dioestrus 1, 2 and 3 by unifying metestrus and dioestrus periods as described by van Cappellen et al. (1997) . The rats in groups 2 and 3 were respectively treated with subcutaneous injections of Menotropin and Urofollitropin using the following scheme: dioestrus-1, 10.00 h (2.5 IU), 17.00 h (1 IU); dioestrus-2, 10.00 h (1 IU), 17.00 h (0.5 IU) and dioestrus-3, 10.00 h (0.5 IU), 17.00 h (0.5 IU) and were killed at 10.00 h on pro-oestrus. The control group received the same dose of solvent subcutaneously in dioestrus 1, 2, 3, and was sacrificed for the experimental process at 10.00 h on pro-oestrus.
Ovariectomy
To minimize the possible influence of estrogen and progesterone, which might have provoked myoelectrical activity in the ovulation induction group, the remaining animals (n ¼ 15) underwent ovariectomy (OVX) following the established protocol in the literature (Hascalik et al., 2005) . Ten days after the surgical procedure, the ovariectomized animals were equally divided into three groups. Group 1 (control) received solvent. Groups 2 and 3 received Urofollitropin and Menotropin, respectively. The rats received subcutaneous injections of Urofollitropin and Menotropin using the same scheme discussed in ovulation induction group.
Measurement of myoelectrical activity
The recording of the uterine myoelectrical activity was conducted with a BIOPAC MP100 A-CE data acquisition system (model MP100; version 3.7.2; Goleta, CA, USA) with a 1000 preamplifier gain (this preamplifier gain was compensated later through signal processing) and a sampling frequency of 500 Hz. Seventeen hours after the last injection, each rat in ovulation induction (on the expected day of pro-estrus at 10:00 h) and OVX groups (on the 14th day of castration) underwent laparotomy, and bipolar electrodes were subserously implanted into their uterine horn with 1-cm interelectrode spacing. The reference electrode was placed on the left leg, and the uterine electrical activity was recorded for at least 3 min under anesthesia. The signals were analyzed in Matlab (version 6; The MathWorks, Natick, MA, USA) environment. Then the uterine horns and ovaries of superovulated rats were excised and processed for histological and immunohistochemical studies.
Histological evaluation
In order to understand the level of mitotic indices of the endometrium, formalin-fixed uterine horns were embedded in paraffin and cut into 5 mm thick sections. Afterward these slices were stained with hematoxylin and eosin, proliferating cell nuclear antigen (PCNA) and Ki67 immunohistochemistry. All proliferating nuclei in the stromal cells, glandular and luminal epithelial cells were stained with mouse monoclonal antibody against PCNA (Clone PC10; Sigma corp; Missouri, USA); a nuclear protein whose expression peaks during the S phase of the cell cycle, and has been used previously to identify proliferating cells. Monoclonal anti-PCNA, clone PC10, from mouse ascites fluid were diluted to 1/1000 and applied to 5 mm paraffined uterine sections, and deparaffinized in xylene using labeled streptavidin biotin method. The sections, for Ki67 detection, were incubated in 10 mmol/l citrate buffer (pH 6.0) at 988C for 20 min, and then quenched in Super Block (ScyTek Laboratories, Utah, USA) for 5 min at room temperature. Primary antibodies for Ki67 (rabbit polyclonal, ready to use ScyTek Laboratories, Utah, USA) were applied to the samples and incubated at room temperature for 30 min. Immunodetection was performed using Ultra Tek horse-radish peroxidase (HRP) Anti-Polyvalent Lab Pack (ScyTek Laboratories, Utah, USA). Ki67 was expressed in the cell during M, G1, S and G2 phases of cell cycle and was absent in resting cells (Go). It showed a good correlation to mitotic indices in human endometrium. In each case the final products were visualized by aminoethylcarbazole chromogen and counterstaining was performed with hematoxylin.
A semi-quantitative grading system was used to score the degree of histologic change of endometrium. The ovarian morphologic features were also assessed in terms of primordial, primary and pre-antral follicles. For follicular classification at least two tissue sections for each ovary were analyzed. In each section, all follicles within carefully selected 10 regions (Â300 magnification) were scored according to Hutt et al. (2006) . This is the primordial follicles are those surrounded by a single layer of flattened granulosa cells, the primary follicles are those surrounded by a single layer of cuboidal granulosa cells and oocytes of pre-antral follicles are those surrounded by more than two layers of granulosa cells filled by follicular fluid. 
Statistical analysis
The Statistical Package for Social Sciences, version 11.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Individual group parameters were firstly assessed with one sample Kolmogorov-Smirnov Z-test, but were found to be not normally distributed. Therefore Mann-Whitney U-test was used to detect statistically significant differences between the animals given Urofollitropin and Menotropin. P , 0.05 was considered statistically significant. Here the results are given as the mean value + standard deviation (SD).
Results
Signal analysis
As we had mentioned in our previous studies (Celik et al., 2008a, b) , the overall pattern of uterine electrical signal shows non-stationary characteristics even during the course of the same experiment. The burst potentials emerging in the signal give way to uterine contractions. Individual temporal signals, because of being in different phases, did not provoke easily perceptible characteristics to acquire significant quantitative results. However, it is considered that the effect of a drug on uterus, if there is one, can change the spectrum of the uterine signal. In our previous study (Celik et al., 2008a) correlation of uterine signal's characteristics to uterine physiological events had been partly illuminated. From the same perspective, a spectrally coherent signal, c( f ), was derived from the spectrums of uterine signal, and from this spectral signal a temporal signal, c(t), was obtained by the use of inverse Fourier transformation. The obtained signal was considered as the embedded component showing the characteristics of the uterine signal that can be modulated by the biasing preparations (FSH based drugs). In Figs. 1, 2 and 3 the impact of HP-uFSH (Urofollitropin) and hMG (Menotropin) components on the temporal variation of c(t) and consequently the coherent-spectrum c( f ) of the uterine signals have been demonstrated. The temporal signals did not demonstrated easily understandable markers which may show the superiority of one compound to another. However, the c( f ), signals showed differentiable characteristics. In the control group, beside of low frequency components c( f ) showed distinguishable components around 0.8 Hz, 1.6 Hz, and a minor component on 2.3 Hz. with a decaying amplitude as frequency advances. In case of the ovariectomized subjects the components remaining under 0.5 Hz were almost completely suppressed. The 0.8 Hz component was spectrally shifted to 0.6 Hz with a distinguishable elevation and the 1.6 Hz was also shifted to a frequency band centered over 1.1 Hz with a dramatic dispersion. Apparently Menotropin suppressed the 0.8 and 1.6 Hz components but with a highly increased amplitude spectrum compared with the control group (for comparison take a note of change of scale in the figures). In a similar fashion Menotropin suppressed the 0.8 and 1.6 Hz spectral components observed in the ovariectomized subjects, and overall the spectrum is further suppressed in the ovariectomized group. Urofollitropin, on the other hand, much reduced these spectral components (0.8 and 1.6 Hz) with a minor elevation in the low frequency spectrum. In ovariectomized rats the Urofollitropin completely reduced these components together with low frequency components except the very low components come out just above DC level. In this case the overall amplitude scale of the spectrum was increased.
The time-frequency representations, shown in Fig. 3 , more precisely demonstrated the spectro-temporal harmony of the energy of uterine signals. As can be seen, each individual drug shows quite different effects on the uterus signal. From these 3D representations the effect of each FSH preparation can be clearly observed. As it is seen highly purified urinary FSH (Urofollitropin) shows a dominant effect over human menopausal FSH (Menotropin) in terms of efficiency in reducing the vibrating spectral components those causing uterine relaxation. From this result it seems that Urofollitropin may be comparable to the recombinant FSH discussed in our previous work (Celik et al., 2008b) . Furthermore, to perform a quantitative analysis regarding the effects of these gonadotrophins some global measures such as the emitted mean-power/second, the standard deviation/ second of the recorded electrical activity were measured and presented in Table I . This shows that the Urofollitropin has a better performance in terms of reducing the power emitted per second compared with Menotropin (6.58 + 0.4 Â 10 29 versus 14.25 + 0.8 Â 10 29 , P ¼ 0.001). 
Histology
Both highly purified urinary FSH (Urofollitropin) and human menopausal FSH (Menotropin) were very well tolerated by animals (only in one of local injection site erythema was observed after Menotropin administration). Neither systemic adverse effects and nor severe hyperstimulation syndrome were observed. As shown in Table I , no statistically significant differences in endometrium or decidualization of stroma were detected through PCNA and Ki67 staining in either Urofollitropin or Menotropin groups. The average scores of the PCNA (1.4 + 0.5 versus 1.6 + 0.5, P ¼ 0.533) and Ki67 (1.6 + 0.4 versus 1.6 + 0.5, P ¼ 0.569) stained endometrial cells in the Urofollitropin and Menotropin groups were comparable. Also a statistically significant difference was not detected between the mean number of primordial follicles (1.8 + 0.4 versus 1.8 + 0.4, P . 0.05), primary follicles (2.0 + 0.0 versus 2.0 + 0.0 P . 0.05) and pre-antral follicles in Urofollitropin and Menotropin administrated groups (2.2 + 0.0 versus 2.0 + 0.0, P ¼ 0.454). The mean number of pre-antral follicles in the Menotropin (2.0 + 0.0 versus 0.6 + 0.5, P ¼ 0.001) and Urofollitropin (2.2 + 0.0 versus 0.6 + 0.5, P ¼ 0.001) administrated subjects was higher than in the control subjects.
Discussion
In addition to ovarian stimulation, the FSH preparations have an active role in the physiological mechanism by which uterine relaxation and/ or contractions are regulated (Mizrachi and Shemesh, 1999a, b; Shemesh, 2001) . From the results we obtained, it was found that beside a trivial dispersal in the whole energy of the signal, compared with the controls, some spectral components of the uterine signal lying within 0.5-3 Hz frequency band are suppressed or modified in response to Urofollitropin and Menotropin. This manifestation may be linked to the role of FSH on the uterus' smooth muscles as follows. It has been reported that the tissues like oviduct, myometrium, endometrium, cervix, and the uterine vessels do accommodate FSH receptors (Ziecik et al., 1992) . The existence of LH and FSH receptors in the uterus is associated with the same transduction pathways as in the ovary and testes (Marsh, 1975; Davis, 1987) . FSH stimulates production of cAMP that is mainly produced by adenylate and inositol phosphate signaling pathways, and this causes uterine relaxation (Berridge, 1993; Dufau, 1998; Mizrachi and Shemesh, 1999a, b; Shemesh, 2001) . The rFSH, HP-uFSH and hMG compounds used in IVF processes could therefore bring about quiescence in the uterus as well as regulating the pituitary FSH, because they have similar bioactivities (Wolfenson et al., 2005) . Although recombinant compounds are produced from Chinese Hamster's ovary cells transfected with the human FSH subunit genes, urinary compounds are traditionally derived from the urine of post-menopausal women. With the progress in purification process the HP-uFSH, which contains less than 0.001 IU of LH per FSH ampoule and has low proteinic contamination (Howles, 1996; Al-Inany and Afnan, 2002) , turned out to be comparable to rFSHs. Nonetheless, the involved purification processes can cause a discrepancy in their efficiency in regulating uterine myoelectrical activity.
Thus far, we have demonstrated the effect of estrogen, progesterone and hCG on the myometrial activity and the effect of rFSH preparations on the uterine electrical activity in rats (Celik et al., 2008a, b) . It was shown that the suppression of some of spectral components in c( f ) derived from uterine signal is due to the increase of FSH level in the smooth muscle cells of the myometrium achieved with the FSH administration, not due to the increased secretion of the estrogens and progesterone from ovaries to the myometrium. This finding is in line with the statement found in the literature that the presence of Figure 2 Coherent spectral characteristics of the mean-signal, c( f ), obtained from the uterus of rats.The figure demonstrates the signals' spectra, and the effect of FSH compounds on the particular 0.8 and 1.6 Hz frequency components which have been discussed in the text as well as the whole signal power.
Urinary FSH and uterine quiescence FSH receptors in the myometrium brought about the possibility of modifying myometrial action potentials independent of estrogens and progesterone with FSH preparations (Kornyei et al., 1996) .
We now understand that with FSH administration, the FSH level in the circulatory system and thereby in the uterine myometrium further increases, and eventually it affects the spectral density of uterine signal. Furthermore, as can be seen from our results shown in Figs. 2 and 3 the 0.8 and 1.6 Hz spectral components emerged in the c( f ) from control subjects were modified and the lower frequency band was suppressed after OVX.
As the subjects were administrated with Menotropin the spectrum was slightly modified so that the 0.8 and 1.6 Hz components could not be detected only a dispersed spectrum over 0.5 -2 Hz was observed. The overall spectrum also reduced in case of OVX. As shown in Figs. 2 and 3 when the subjects were administrated with Urofollitropin, the spectrum was much apparently modified so that the 0.8 and 1.6 Hz components completely suppressed compared with both control and OVX-control groups with an increase in the overall spectrum. Possibly this response can be attributed to a spectral component involved in uterine contractions rather than the whole signal power as has been mentioned earlier (Celik et al., 2008a) . It is hypothesized that the increase in the signal's power, particularly the highly synchronized low frequency components those remaining under 0.5 Hz, may not lead to uterine contractions but supply an electrical energy to uterine muscles which may induce a stress on the myometrium. This stress, if it is true, may have an effect on the success rate of IVF. However, to clarify this speculation a comparative systematic study needs to be performed. The difference detected in the electrical activity of uterus administrated with urinary compounds is perhaps due to the LH level rather than FSH (IU/mg protein) level in the myometrium which may be implicitly associated with the ingredients of Urofollitropin and Menotropin compounds.
As given in Table I , the emitted mean power/second in the Menotropin and Urofollitropin administrated subjects were higher than in the control subjects in both ovulation induction and ovariectomized rats. These global measures can also be linked to the efficiency and consistency of these two urinary FSH compounds in controlling the uterine contractions.
In this study, any distinguishable differences in endometrium or decidualization of stroma were not detected through PCNA and Ki67 staining in all rat groups. This suggests that endometrial cells do not undergo a significant proliferation, and Urofollitropin and Menotropin do not have a negative effect on stroma during ovulation induction. Other studies that comparing such FSH compounds in women having ovulation problems suggest no differences in follicular development (Dickey et al., 2003) , and E2 levels during stimulation supporting the similarity of the main pharmacodynamic properties of these compounds (Balen et al., 2007) .
In conclusion, this preliminary study showed that highly purified urinary FSH and human menopausal FSH may be comparable in terms of their effects on follicle development (number oocytes) and histology of endometrium. These two compounds have an obvious effect on the myometrial electrical activity as regulating signal power particularly around 0.8 and 1.6 Hz spectral terms and we hypothesize that these effects may involve the uterine regulating mechanism. The results also evidently showed the superiority of Urofollitropin over Menotropin in terms of suppression of these spectral components and may lead to quiescence of uterine contractions which is essential for IVF. This variation may be linked to strategies followed in their development and purification. We also suggest that both of these compounds, but particularly Urofollitropin can be safely and effectively used to induce ovulation induction without leading to any unexpected uterine contractions. The obtained results give rise to clues about the possible role of Urofollitropin and Menotropin in human extra-gonadal tissues, which could also affect IVF success rates. However, further study on extra-gonadal effects of these drugs and the functional role underlying the integrative mechanisms between myometrium and endometrium is needed.
Author's Role 
